Crossmark

Practice patterns in chronic graft-versus-host disease patient management and patient reported outcome measures across the EBMT allogeneic transplantation network

Crossref DOI link: https://doi.org/10.1038/s41409-022-01733-3

Published Online: 2022-06-11

Published Print: 2022-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Perovic, Vladimir https://orcid.org/0000-0002-1994-1738
Sabol, Ivan https://orcid.org/0000-0002-5753-8528
Grce, Magdalena https://orcid.org/0000-0001-6178-8418
Inngjerdingen, Marit

Pulanic, Drazen

Peric, Zinaida https://orcid.org/0000-0001-9458-8025
Peczynski, Christophe https://orcid.org/0000-0002-3829-0088
Polge, Emmanuelle

Koenecke, Christian https://orcid.org/0000-0001-7025-1735
Dickinson, Anne

Greinix, Hildegard

Basak, Grzegorz

Penack, Olaf https://orcid.org/0000-0003-4876-802X
Scherwath, Angela

Barata, Anna https://orcid.org/0000-0003-0297-5920
Olivieri, Attilio

Lawitschka, Anita https://orcid.org/0000-0002-4843-4735
Mensah-Glanowska, Patrycja https://orcid.org/0000-0002-9850-2206
Andrikovics, Hajnalka

Schoemans, Helene https://orcid.org/0000-0002-7568-8239
Wolff, Daniel
Funding

Funding for this research was provided by:

European Cooperation in Science & Technology under the COST Action 17138

European Cooperation in Science and Technology (COST), COST Action 17138

European Cooperation in Science & Technology under the COST Action 17138

European Cooperation in Science & Technology under the COST Action 17138

European Cooperation in Science & Technology under the COST Action 17138

European Cooperation in Science & Technology under the COST Action 17138

European Cooperation in Science & Technology under the COST Action 17138

European Cooperation in Science & Technology under the COST Action 17138

European Cooperation in Science & Technology under the COST Action 17138

European Cooperation in Science & Technology under the COST Action 17138

European Cooperation in Science & Technology under the COST Action 17138

European Cooperation in Science & Technology under the COST Action 17138

European Cooperation in Science & Technology under the COST Action 17138
License Information

Text and Data Mining valid from 2022-06-11

Version of Record valid from 2022-06-11
More Information

Article History

Received: 1 August 2021

Revised: 26 May 2022

Accepted: 30 May 2022

First Online: 11 June 2022

Competing interests

: DW received honoraria from Novartis, Mallinckrodt, MACO, Janssen, Behring and Incyte. Between 2017 and 2021, H.S. has participated in the Advisory Boards for Incyte, Janssen & Novartis; received speaker’s fees from Novartis, Incyte, Jazz Pharmaceuticals, Takeda and the BHS (Belgian Haematological Society); received travel grants from the EBMT, the CIBMTR, Celgene, Abbvie, Incyte & Gilead and research funding from Novartis and the BHS. All other authors declare no conflict of interest. OP has received honoraria or travel support from Astellas, Gilead, Jazz, MSD, Neovii Biotech, Novartis, Pfizer and Therakos. He has received research support from Gilead, Incyte, Jazz, Neovii Biotech and Takeda. He is a member of advisory boards to Jazz, Gilead, MSD, Omeros, Priothera, Shionogi and SOBI. Other authors declare no competing interests.

Document is current

Any future updates will be listed below